View 
FILTERS (0)
* Not connected to ResearchPool

MORE FILTERS

  
reports
Fehmi Ben Naamane ... (+2)
  • Fehmi Ben Naamane
  • Johanna Jourdain
Fehmi Ben Naamane ... (+2)
  • Fehmi Ben Naamane
  • Johanna Jourdain
Ana Arjona-Martinez ... (+2)
  • Ana Arjona-Martinez
  • Yan Derocles
Ana Arjona-Martinez ... (+2)
  • Ana Arjona-Martinez
  • Yan Derocles
 PRESS RELEASE

Sodexo: Combined Shareholders Meeting of December 16, 2025

Sodexo: Combined Shareholders Meeting of December 16, 2025 Issy-les-Moulineaux, December 16, 2025 Sodexo's Annual Shareholders Meeting was held on Tuesday, December 16, 2025 at the Seine Musicale auditorium in Boulogne-Billancourt, chaired by Sophie Bellon, Chairwoman of the Board of Directors. Quorum was established at 87.28%, and 3,298 shareholders were present, represented or voted by correspondence. All the resolutions proposed by the Board of Directors were adopted, notably:• the adoption of the financial statements for Fiscal 2025;• the dividend of €2.70 per share, to be paid on D...

 PRESS RELEASE

Sodexo : Assemblée Générale mixte du 16 décembre 2025

Sodexo : Assemblée Générale mixte du 16 décembre 2025 Issy-les-Moulineaux, le 16 décembre 2025 L’Assemblée Générale annuelle des actionnaires de Sodexo s’est tenue ce mardi 16 décembre 2025 à l’auditorium de la Seine Musicale à Boulogne-Billancourt, sous la présidence de Sophie Bellon, Présidente du Conseil d’Administration. Le quorum s’est établi à 87,28% et 3 298 actionnaires étaient présents, représentés ou ont voté par correspondance. Toutes les résolutions proposées par le Conseil d’Administration ont été adoptées, et notamment celles concernant : • l’approbation des comptes sociau...

Dominic Rose ... (+2)
  • Dominic Rose
  • Naresh Chouhan

Thematic - 2026 Outlook - "5 More Years" (55pgs)

For access to the full note, please contact Naresh Chouhan ( ) With EU Pharma (ex-Novo) now having reached decade high valuations vs EuroStoxx600, we believe the sector has broken out & the sustainability of the growth profile will now generate continued strong performance. Consensus 5yr sales & EPS CAGR’s stand at 4% & 7% for 15x 2026 PE. We show there is upside to this from underestimated pipelines where cons. rarely fully models “monster” drugs & from M&A which we expect to be strong at JPM ...

 PRESS RELEASE

Novartis breaks ground on flagship manufacturing hub in North Carolina

Novartis breaks ground on flagship manufacturing hub in North Carolina FDA Commissioner Marty Makary, North Carolina Governor Josh Stein and Novartis leadership highlight importance of new hub to US patients and local economyConstruction reflects company’s commitment to ensure end-to-end manufacturing of all key medicines for US patients in the US at scaleGroundbreaking marks continuation of Novartis investment and growth in the US, capping year of significant regulatory and manufacturing milestones East Hanover, December 12, 2025 – Novartis, a leading global innovative medicines company...

Ana Arjona-Martinez ... (+2)
  • Ana Arjona-Martinez
  • Yan Derocles

Pernod-Ricard: 1 director

A director at Pernod-Ricard bought 525 shares at 75.800EUR and the significance rating of the trade was 54/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clearly sh...

Loading...
New interest

Save your current filters as a new Interest

Please enter a name for this interest

Email alerts

Would you like to receive real-time email alerts when a new report is published under this interest?

Save This Search

These search results will show up under 'Saved searches' in the left panel

Please enter a name for this saved search

ResearchPool Subscriptions

Get the most out of your insights

Get in touch